Advertisement
Pharma/Biotech News
Subscribe to Pharma/Biotech News

The Lead

Gilead Releases Phase 2 Pancreatic Cancer Data

September 17, 2014 3:28 pm | News | Comments

Gilead Sciences Inc. announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. Read more...

Covance, Frenova Renal Research Collaborate on Kidney, Renal Diseases

September 17, 2014 3:24 pm | News | Comments

Covance Inc. and Frenova Renal Research announced...

Lilly Sells Failed Oncology Drug to Denovo Biopharma

September 17, 2014 3:18 pm | News | Comments

Denovo Biopharma LLC announced that it has...

Sun Pharma Licenses Merck Psoriasis Drug for $80M

September 17, 2014 3:02 pm | News | Comments

Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

1st Volunteer Gets Experimental Ebola Vaccine

September 17, 2014 12:46 pm | News | Comments

British scientists say a former nurse has become the first person in the country to receive an experimental Ebola vaccine in an early trial to test its safety. Read more...                       

Sanofi Enters Groundbreaking Heart Disease Collaboration with MyoKardia

September 17, 2014 10:57 am | News | Comments

Sanofi and MyoKardia Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. Read more...   

EMD Serono, Sutro Biopharma Partner on ADCs

September 17, 2014 10:52 am | News | Comments

EMD Serono Inc., a subsidiary of Merck KGaA, and Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). Read more...

Advertisement

Merck Diabetes Drug Hits Endpoints in Japanese Study

September 17, 2014 10:44 am | News | Comments

Merck announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. Read more...         

Glenmark's TRPA1 Antagonist Excels in Phase 2a

September 17, 2014 10:33 am | News | Comments

Glenmark Pharmaceuticals announced that its first-in-class Transient Receptor Potential Ankyrin 1 antagonist, GRC 17536, has shown positive data in a Phase 2a study conducted on 138 patients in Europe and India. Read more...       

Auxilium Adopts 'Poison Pill' Plan After $1.41B Offer from Endo

September 17, 2014 10:21 am | News | Comments

The board of Auxilium Pharmaceuticals Inc. has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker. Read more...

Relmada in MOA Agreement With MSKCC

September 16, 2014 3:47 pm | News | Comments

Relmada Therapeutics Inc. announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER. Read more...         

TapImmune Releases Interim Data on Phase 1 Cancer Trial

September 16, 2014 3:39 pm | News | Comments

TapImmune Inc. reported that analysis of the interim data from the first 13 patients in a Phase 1 clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of five naturally processed folate receptor alpha Class II antigenic epitopes. Read more...

Advertisement

Amarin Committed to Completing Cardiovascular Outcomes Study

September 16, 2014 3:34 pm | News | Comments

Amarin Corp. announced its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial) cardiovascular outcomes study. Read more...                 

Mylan to Begin Phase 3 Trials on Key Generics

September 16, 2014 3:28 pm | News | Comments

Mylan Inc. announced it is initiating Phase 3 clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus.  Read more...                   

Nektar Says FDA Clears Constipation Drug Movantik

September 16, 2014 2:41 pm | News | Comments

Nektar Therapeutics said Tuesday that U.S. regulators approved its drug Movantik, a once-per-day treatment for constipation caused by opioid painkillers. Movantik, or naloxegol, is approved for adults who have chronic pain that is not caused by cancer. Read more...

Lilly, AstraZeneca Team Up on Alzheimer's Drug

September 16, 2014 11:43 am | News | Comments

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing. Read more...      

Bayer, Orion Initiate Phase 3 Prostate Cancer Trial

September 16, 2014 10:26 am | News | Comments

Bayer HealthCare and Orion Corp. have begun to enroll patients in a Phase 3 trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer. Read more...

Advertisement

Novo Nordisk's Insulin Shows Long-Term Efficacy in Children, Adolescents

September 16, 2014 10:19 am | News | Comments

Novo Nordisk announced new data from the BEGIN YOUNG 1 trial investigating once-daily Tresiba (insulin degludec) versus insulin detemir, both in combination with bolus insulin aspart in a 52-week trial in children and adolescents with type 1 diabetes. Read more...

Northwest Bio's Cell Therapy Named 'Promising Innovative Medicine'

September 16, 2014 10:04 am | News | Comments

An innovative cell therapy for cancer has become the first designated "promising" as part of a scheme to get medicines to patients quicker. The medicine, named DCVax-L, has been developed by U.S.-based pharmaceutical company Northwest Biotherapeutics Inc. Read more...

Allergan Agrees to Move Forward With Meeting

September 16, 2014 6:41 am | by The Associated Press | News | Comments

Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker. Read more...

NY Suing Actavis to Halt Alzheimer's Drug Swap

September 15, 2014 7:39 pm | by Michael Virtanen | News | Comments

New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses. Read more...

Merck Osteoporosis Drug Meets Primary Endpoint in Phase 3

September 15, 2014 3:49 pm | News | Comments

Merck announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck’s investigational once-weekly cathepsin K inhibitor. Read more...           

FDA Accepts Shire's sNDA for Vyvanse

September 15, 2014 3:43 pm | News | Comments

Shire announced that the FDA has accepted for filing with priority review a supplemental New Drug Application for Vyvanse (lisdexamfetamine dimesylate) capsules as a treatment for adults with binge eating disorder (BED). Read more...     

FDA Committee Backs Approval of Natpara for Treatment of Hypoparathyroidism

September 15, 2014 3:37 pm | News | Comments

NPS Pharmaceuticals Inc. announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted that the available data support the approval of Natpara for the long-term treatment of hypoparathyroidism. Read more...      

Lilly Colorectal Cancer Drug Hits OS Endpoint

September 15, 2014 3:31 pm | News | Comments

Eli Lilly and Co. announced that the RAISE trial, a Phase 3 study of ramucirumab (Cyramza) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. Read more...     

Amgen Heart Study Shows Positive Ivabradine Results

September 15, 2014 3:18 pm | News | Comments

Amgen announced data from the Phase 3 SHIFT study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. Read more...   

Avanir Drug for Alzheimer's Agitation Excels in Trial

September 15, 2014 3:07 pm | News | Comments

Shares of Avanir Pharmaceuticals soared Monday after the company reported positive clinical trial results for a drug that is designed to treat agitation in Alzheimer's disease patients. Read more...                

EMD Serono Announces 2014 GMSI Grant Winners

September 15, 2014 11:29 am | News | Comments

EMD Serono announced the recipients of the second annual Grant for Multiple Sclerosis Innovation at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS). Read more...

Akashi Acquires Global Rights to Novel DMD Treatment

September 15, 2014 11:16 am | News | Comments

Akashi Therapeutics Inc. announced that it has acquired global rights to GsMTx-4, a peptide developed to address calcium level imbalance in muscle, a critical issue in Duchenne muscular dystrophy contributing to loss of function and other associated pathologies. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading